173 related articles for article (PubMed ID: 32383226)
21. Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Suissa S
Diabetes Obes Metab; 2020 Feb; 22(2):254-262. PubMed ID: 31596043
[TBL] [Abstract][Full Text] [Related]
22. Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study.
Chen JM; Chang CW; Lin YC; Horng JT; Sheu WH
J Diabetes Res; 2014; 2014():812628. PubMed ID: 25197673
[TBL] [Abstract][Full Text] [Related]
23. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
24. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.
Chang CH; Chang YC; Lin JW; Chen ST; Chuang LM; Lai MS
J Clin Endocrinol Metab; 2015 Mar; 100(3):1121-9. PubMed ID: 25555040
[TBL] [Abstract][Full Text] [Related]
26. A risk prediction model for heart failure hospitalization in type 2 diabetes mellitus.
Williams BA; Geba D; Cordova JM; Shetty SS
Clin Cardiol; 2020 Mar; 43(3):275-283. PubMed ID: 31837035
[TBL] [Abstract][Full Text] [Related]
27. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
[TBL] [Abstract][Full Text] [Related]
28. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
29. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
[TBL] [Abstract][Full Text] [Related]
30. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
31. Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study.
Chin HJ; Nam JH; Lee EK; Shin JY
Medicine (Baltimore); 2017 Jun; 96(25):e7213. PubMed ID: 28640111
[TBL] [Abstract][Full Text] [Related]
32. Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study.
Chang CH; Lin JW; Chen ST; Lai MS; Chuang LM; Chang YC
Medicine (Baltimore); 2016 Feb; 95(7):e2603. PubMed ID: 26886601
[TBL] [Abstract][Full Text] [Related]
33. Comparative tolerability profiles of oral antidiabetic agents.
Krentz AJ; Ferner RE; Bailey CJ
Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
[TBL] [Abstract][Full Text] [Related]
34. Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years.
Cintra RM; Nogueira AC; Bonilha I; Luchiari BM; Coelho-Filho OR; Coelho OR; Schwartzmann P; Muscellie E; Nadruz W; Carvalho LSF; Sposito AC
J Clin Endocrinol Metab; 2021 Sep; 106(10):3060-3067. PubMed ID: 34125217
[TBL] [Abstract][Full Text] [Related]
35. Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database.
Tanabe M; Nomiyama T; Motonaga R; Murase K; Yanase T
BMC Endocr Disord; 2015 Sep; 15():49. PubMed ID: 26382923
[TBL] [Abstract][Full Text] [Related]
36. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
37. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.
van Dalem J; Brouwers MC; Stehouwer CD; Krings A; Leufkens HG; Driessen JH; de Vries F; Burden AM
BMJ; 2016 Jul; 354():i3625. PubMed ID: 27413017
[TBL] [Abstract][Full Text] [Related]
38. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
39. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
Komamine M; Kajiyama K; Ishiguro C; Uyama Y
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
